• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性胆汁性胆管炎的肝脂肪变性严重程度和脂质特征。

The liver steatosis severity and lipid characteristics in primary biliary cholangitis.

机构信息

Capital Medical University, No 8, Xitoutiao, Youanmenwai, Fengtai District, Beijing, 100069, China.

Capital Medical University, Beijing, China.

出版信息

BMC Gastroenterol. 2021 Oct 22;21(1):395. doi: 10.1186/s12876-021-01974-4.

DOI:10.1186/s12876-021-01974-4
PMID:34686147
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8532358/
Abstract

BACKGROUND

Patients with primary biliary cholangitis (PBC) often have comorbid dyslipidemia, and determining the degree of hepatic steatosis can help predict the risk of cardiovascular events in PBC patients. The aim of our study was to analyze the characteristics of lipid distribution and the degree of hepatic steatosis in PBC.

METHODS

We retrospectively analyzed 479 cases of PBC, chronic hepatitis B (CHB), chronic hepatitis C (CHC), non-alcoholic fatty liver disease (NAFLD), and healthy subjects (Normal) diagnosed by liver biopsy or definitive clinical diagnosis. Controlled attenuation parameter (CAP) values were applied to assess the degree of steatosis of the liver, and lipid levels were also compared in the five cohorts.

RESULTS

We found that among the five groups of subjects, the PBC group had the lowest CAP values (P < 0.001), and the high-density lipoprotein cholesterol (HDL-C) level in the PBC group was higher than normal, CHC and CHB group (P = 0.004, P = 0.033, P < 0.001, respectively).In the multivariate linear analysis, only BMI (β = 1.280, P = 0.028), ALP (β = - 0.064, P = 0.012), TBA (β = - 0.126, P = 0.020), TG (β = 12.520, P = 0.000), HDL-C (β = - 11.338, P = 0.001) and LDL-C (β = 7.012, P = 0.002) were independent predictors of CAP.

CONCLUSIONS

Among PBC, CHB, CHC, NAFLD and healthy subjects, PBC had the lowest degree of hepatic steatosis and higher HDL-C levels, all of which were found to be protective factors against atherosclerosis and cardiovascular risk and would provide a valuable reference for the risk of developing cardiovascular events in PBC patients.

摘要

背景

原发性胆汁性胆管炎(PBC)患者常伴有血脂异常,而肝脂肪变性程度的确定有助于预测 PBC 患者发生心血管事件的风险。本研究旨在分析 PBC 患者的脂类分布特征和肝脂肪变性程度。

方法

回顾性分析了 479 例经肝活检或明确临床诊断的 PBC、慢性乙型肝炎(CHB)、慢性丙型肝炎(CHC)、非酒精性脂肪性肝病(NAFLD)和健康对照(Normal)患者。应用受控衰减参数(CAP)值评估肝脏脂肪变性程度,并比较五组患者的血脂水平。

结果

发现五组受试者中,PBC 组的 CAP 值最低(P<0.001),且 PBC 组的高密度脂蛋白胆固醇(HDL-C)水平高于正常组、CHC 组和 CHB 组(P=0.004、P=0.033、P<0.001)。多因素线性分析显示,仅 BMI(β=1.280,P=0.028)、ALP(β=-0.064,P=0.012)、TBA(β=-0.126,P=0.020)、TG(β=12.520,P=0.000)、HDL-C(β=-11.338,P=0.001)和 LDL-C(β=7.012,P=0.002)是 CAP 的独立预测因素。

结论

在 PBC、CHB、CHC、NAFLD 和健康对照者中,PBC 患者的肝脂肪变性程度最低,HDL-C 水平最高,均为动脉粥样硬化和心血管风险的保护因素,为预测 PBC 患者发生心血管事件的风险提供了有价值的参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1da/8532358/94a78b3f9086/12876_2021_1974_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1da/8532358/026a73042057/12876_2021_1974_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1da/8532358/c375a69fdeff/12876_2021_1974_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1da/8532358/94a78b3f9086/12876_2021_1974_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1da/8532358/026a73042057/12876_2021_1974_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1da/8532358/c375a69fdeff/12876_2021_1974_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1da/8532358/94a78b3f9086/12876_2021_1974_Fig3_HTML.jpg

相似文献

1
The liver steatosis severity and lipid characteristics in primary biliary cholangitis.原发性胆汁性胆管炎的肝脂肪变性严重程度和脂质特征。
BMC Gastroenterol. 2021 Oct 22;21(1):395. doi: 10.1186/s12876-021-01974-4.
2
Concomitant nonalcoholic fatty liver disease does not alter the activity, severity or course of primary biliary cholangitis.合并非酒精性脂肪性肝病不会改变原发性胆汁性胆管炎的活动度、严重程度或病程。
Liver Int. 2018 Jun;38(6):1110-1116. doi: 10.1111/liv.13644. Epub 2017 Dec 15.
3
The impact of primary biliary cholangitis on non-alcoholic fatty liver disease.原发性胆汁性胆管炎对非酒精性脂肪性肝病的影响。
Eur J Gastroenterol Hepatol. 2021 Apr 1;33(4):565-570. doi: 10.1097/MEG.0000000000001782.
4
Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.慢性乙型肝炎患者与慢性丙型肝炎患者及非酒精性脂肪性肝病患者相比,脂肪变性和胰岛素抵抗的患病率
Eur J Intern Med. 2015 Jan;26(1):30-6. doi: 10.1016/j.ejim.2014.12.001. Epub 2014 Dec 29.
5
Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.氧化型低密度脂蛋白抗体/高密度脂蛋白胆固醇比值与晚期非酒精性脂肪性肝病瘦患者有关。
J Gastroenterol Hepatol. 2016 Sep;31(9):1611-8. doi: 10.1111/jgh.13335.
6
High prevalence of lower limb atherosclerosis is linked with the gut-liver axis in patients with primary biliary cholangitis.原发性胆汁性胆管炎患者下肢动脉硬化的高发与肠道-肝脏轴有关。
Liver Int. 2023 Feb;43(2):370-380. doi: 10.1111/liv.15463. Epub 2022 Nov 11.
7
The clinical value of the monocyte to high-density lipoprotein cholesterol ratio and alkaline phosphatase-to-platelet ratio in primary biliary cholangitis.单核细胞/高密度脂蛋白胆固醇比值和碱性磷酸酶/血小板比值在原发性胆汁性胆管炎中的临床价值。
Medicine (Baltimore). 2023 Oct 13;102(41):e35454. doi: 10.1097/MD.0000000000035454.
8
[Value of controlled attenuation parameter in diagnosis of fatty liver using FibroScan].[受控衰减参数在使用FibroScan诊断脂肪肝中的价值]
Zhonghua Gan Zang Bing Za Zhi. 2016 Feb;24(2):108-13. doi: 10.3760/cma.j.issn.1007-3418.2016.02.007.
9
Patterns of serum lipids derangements and cardiovascular risk assessment in patients with primary biliary cholangitis.原发性胆汁性胆管炎患者的血脂紊乱模式和心血管风险评估。
Ann Hepatol. 2019 Nov-Dec;18(6):879-882. doi: 10.1016/j.aohep.2019.07.006. Epub 2019 Aug 22.
10
The association of the steatosis severity, NAFLD fibrosis score and FIB-4 index with atherogenic dyslipidaemia in adult patients with NAFLD: A cross-sectional study.非酒精性脂肪性肝病患者非酒精性脂肪性肝病纤维化评分、脂肪变性严重程度与 FIB-4 指数与动脉粥样硬化性血脂异常的关系:一项横断面研究。
Int J Clin Pract. 2021 Jun;75(6):e14131. doi: 10.1111/ijcp.14131. Epub 2021 Mar 21.

引用本文的文献

1
The relationship between dyslipidemia and chronic liver disease, with the mediating role of depressive symptoms.血脂异常与慢性肝病之间的关系,以及抑郁症状的中介作用。
Front Public Health. 2025 Aug 25;13:1581622. doi: 10.3389/fpubh.2025.1581622. eCollection 2025.
2
Clinical characteristics of dyslipidemia in patients with primary biliary cholangitis: a single-center experience in China.原发性胆汁性胆管炎患者血脂异常的临床特征:中国单中心经验
Clin Rheumatol. 2025 Sep 5. doi: 10.1007/s10067-025-07662-y.
3
Primary Biliary Cholangitis: Immunopathogenesis and the Role of Bile Acid Metabolism in Disease Progression.

本文引用的文献

1
Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.亚太地区的肝脏疾病:《柳叶刀·胃肠病学和肝脏病学》专刊。
Lancet Gastroenterol Hepatol. 2020 Feb;5(2):167-228. doi: 10.1016/S2468-1253(19)30342-5. Epub 2019 Dec 15.
2
Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.《2019年丙型肝炎指南更新:美国肝病研究协会-美国传染病学会关于丙型肝炎病毒感染检测、管理及治疗的建议》
Hepatology. 2020 Feb;71(2):686-721. doi: 10.1002/hep.31060.
3
原发性胆汁性胆管炎:免疫发病机制及胆汁酸代谢在疾病进展中的作用
Int J Mol Sci. 2025 Aug 16;26(16):7905. doi: 10.3390/ijms26167905.
4
Concurrent nonalcoholic fatty liver disease may decrease liver fibrosis severity in patients with primary biliary cholangitis.合并存在的非酒精性脂肪性肝病可能会降低原发性胆汁性胆管炎患者的肝纤维化严重程度。
BMC Gastroenterol. 2025 Jul 30;25(1):541. doi: 10.1186/s12876-025-04145-x.
5
Magnetic resonance evaluation of three-dimensional liver fat fraction by hepatitis C status and associations with inflammatory cytokines.丙型肝炎状态对肝脏三维脂肪分数的磁共振评估及其与炎性细胞因子的关联
PLoS One. 2025 Jul 23;20(7):e0327668. doi: 10.1371/journal.pone.0327668. eCollection 2025.
6
Patients with AMA/anti-sp100/anti-gp210 Positivity and Cholestasis Can Manifest Conditions Beyond Primary Biliary Cholangitis.AMA/抗sp100/抗gp210阳性且伴有胆汁淤积的患者可能表现出原发性胆汁性胆管炎以外的病症。
J Clin Transl Hepatol. 2025 Mar 28;13(3):200-206. doi: 10.14218/JCTH.2024.00374. Epub 2025 Jan 17.
7
Nonlinear associations of the hs-CRP/HDL-C index with metabolic dysfunction-associated steatotic liver disease and advanced liver fibrosis in US adults: insights from NHANES 2017-2018.美国成年人中hs-CRP/HDL-C指数与代谢功能障碍相关脂肪性肝病及晚期肝纤维化的非线性关联:来自2017 - 2018年美国国家健康与营养检查调查(NHANES)的见解
Sci Rep. 2025 Feb 3;15(1):4029. doi: 10.1038/s41598-025-88685-y.
8
Association between the ratio of serum uric acid to high-density lipoprotein cholesterol and liver fat content: evidence from a Chinese health examination dataset.血清尿酸与高密度脂蛋白胆固醇比值与肝脏脂肪含量之间的关联:来自中国健康体检数据集的证据。
Sci Rep. 2024 Dec 28;14(1):31397. doi: 10.1038/s41598-024-83013-2.
9
Development and external validation of an early prediction model to identify irresponsive patients and prognosis of UDCA treatment in primary biliary cholangitis.一种用于识别原发性胆汁性胆管炎中对熊去氧胆酸治疗无反应患者及预后的早期预测模型的开发与外部验证
Sci Rep. 2024 Dec 28;14(1):31369. doi: 10.1038/s41598-024-82854-1.
10
Bilirubin bioconversion to urobilin in the gut-liver-kidney axis: A biomarker for insulin resistance in the Cardiovascular-Kidney-Metabolic (CKM) Syndrome.胆红素在肠-肝-肾轴中生物转化为尿胆素:心血管-肾脏-代谢(CKM)综合征中胰岛素抵抗的生物标志物。
Metabolism. 2025 Feb;163:156081. doi: 10.1016/j.metabol.2024.156081. Epub 2024 Nov 22.
Systematic review: chronic viral hepatitis and metabolic derangement.
系统评价:慢性病毒性肝炎与代谢紊乱
Aliment Pharmacol Ther. 2020 Jan;51(2):216-230. doi: 10.1111/apt.15575. Epub 2019 Nov 20.
4
Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis.真菌参与原发性硬化性胆管炎患者肠道微生物失调。
Gut. 2020 Jan;69(1):92-102. doi: 10.1136/gutjnl-2018-317791. Epub 2019 Apr 19.
5
Association between chronic viral hepatitis and metabolic syndrome in southern Taiwan: a large population-based study.台湾南部慢性病毒性肝炎与代谢综合征的相关性:一项大型基于人群的研究。
Aliment Pharmacol Ther. 2018 Nov;48(9):993-1002. doi: 10.1111/apt.14960. Epub 2018 Sep 11.
6
Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis.非酒精性脂肪性肝病患者的高密度脂蛋白胆固醇流出能力受损与亚临床动脉粥样硬化有关。
Sci Rep. 2018 Aug 3;8(1):11691. doi: 10.1038/s41598-018-29639-5.
7
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.慢性乙型肝炎的预防、诊断和治疗最新进展:美国肝病研究学会2018年乙型肝炎指南
Hepatology. 2018 Apr;67(4):1560-1599. doi: 10.1002/hep.29800.
8
The correlation of controlled attenuation parameter results with ultrasound-identified steatosis in real-world clinical practice.在真实临床实践中,受控衰减参数结果与超声识别的脂肪变性的相关性。
J Formos Med Assoc. 2017 Nov;116(11):852-861. doi: 10.1016/j.jfma.2017.08.010. Epub 2017 Sep 6.
9
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.非酒精性脂肪性肝病的诊断与管理:美国肝病研究协会的实践指南
Hepatology. 2018 Jan;67(1):328-357. doi: 10.1002/hep.29367. Epub 2017 Sep 29.
10
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.EASL 临床实践指南:原发性胆汁性胆管炎患者的诊断和管理。
J Hepatol. 2017 Jul;67(1):145-172. doi: 10.1016/j.jhep.2017.03.022. Epub 2017 Apr 18.